Background: In laboratory setting evaluating the agreement between two measurement methods is a very frequent practice. Unfortunately, the guidelines to refer to are not free from criticisms from a statistical methodological point of view. We reviewed the Clinical and Laboratory Standards Institute guideline EP09c, 3rd ed. pointing out some drawbacks and some aspects that have not been well defined, leaving situations of uncertainty and/or of excessive subjectivity in the judgement. Content: We have stressed the need of having replicates to estimate the systematic and the proportional biases of the measurement methods to be compared. Indeed, unequal variance of the two measurement methods gives a slope and intercept of the regression between the difference and the mean of the two values of the measurement methods to be compared that can be absolutely calculated from their means, their variances and their correlation coefficient. So, it is not possible to disentangle true from spurious biases. For laboratory professionals we have developed a worked exemplification of an agreement assessment. Summary: We have stressed the need of other approaches than the classic Bland and Altman method to calculate the systematic and proportional biases of two measurement methods compared for their agreement in a study with replicates.

With most global healthcare resources focused on COVID-19, altered resource allocation is disrupting the continuum of care for chronic endocrine conditions, including acromegaly. In order to assess the effects of COVID-19 on care of patients with acromegaly, we conducted an international online survey of endocrinologists. The questionnaire was drafted by a Steering Committee of acromegaly experts and covered both respondent demographics, contact and communication with patients, and patient care. Respondent awareness was generated through social media campaigns and the survey completed online using Google forms. The majority of endocrinologists who responded (N = 84) were based in Europe (67.9%) and were female (58.3%). Slightly more than half of respondents worked in a specialized pituitary center (52.4%) and a large minority cared for more than 50 acromegaly patients (47.6%). Most respondents (85.7%) indicated surgery was their first-line treatment, with only 14.3% indicating medical therapy as a first-choice treatment option. One-third (33.3%) of respondents reported having delayed a planned surgery due to a lack of COVID-19 testing provision and 54.8% due to a lack of surgical provision; 19.1% indicated that a lack of personal protective equipment had reduced their ability to treat patients with acromegaly. Just 21.4% of respondents reported no negative effects from the pandemic on diagnostic practice patterns, and just 19.1% reported no negative effect on patient follow-up practices. Many respondents (55.9%) indicated that remote methods had improved their ability to communicate with their patients and 69.0% indicated that they would continue to use methods of consultation necessitated by the COVID-19 pandemic. Our data suggest the COVID-19 pandemic is substantially affecting the care of acromegaly. However, these results also suggest that endocrinologists are embracing aspects of the ‘new normal’ to create a novel continuum of care better suited to the presumed post-COVID-19 environment. The goal of these changes must be both to improve care while shielding patients from more severe involvement in concomitant acute illnesses such COVID-19.

In addition to the power of the statistical test, sample size calculations should consider the precision of the effect estimate. The expected width of the “exact” confidence interval, based on inverting the binomial test, is an appropriate measure of the latter together with the probability of obtaining, under the alternative hypothesis, confidence intervals with a width less than the expected one. In testing a proportion against a reference value, we devised a “two-step” procedure. At the first step the required sample size for the binomial testing is obtained; then, at the second step, this sample size is iteratively increased until the probability of obtaining “exact” confidence intervals with a width less than the expected one exceeds a required threshold.

278 azathioprine and methylprednisolone (AZA)-treated and 406 ciclosporin (CS) treated patients with a kidney graft functioning for more than 1 year were investigated for the presence of chronic liver disease (CLD), defined as an increase in transaminases of 1.5 times the upper normal limits for a period of at least 12 months. The prevalence of CLD was 36 and 27% in the two groups, respectively. The univariate analysis showed that male sex, alcohol abuse and HBsAg positivity correlated with CLD onset in the AZA group while blood transfusions, length of dialysis treatment, pretransplantation CLD, HBsAg positivity and ferritin levels over 800 ng/ml correlated with CLD onset in CS. The multivariate analysis identified male sex and HBsAg positivity in the AZA group and age over 18 years, high ferritin levels and HBsAg positivity in the CS group as risk factors predictive of CLD onset. Liver failure represented the 4th cause of death in the AZA group but 1 of the 2 most important causes of death in CS in the long term. However, these drawbacks were overcome by the overall low mortality rate in CS. Therefore, renal transplantation should not be refused to patients positive for HBsAg and/or with preexisting liver disease.